Polyclonal Antibody to Tumor Necrosis Factor Alpha Induced Protein 3 Interacting Protein 2 (TNIP2)
| Code | Size | Price |
|---|
| PAF805Mu01-20ul | 20ul | £88.00 |
Quantity:
| PAF805Mu01-100ul | 100ul | £165.00 |
Quantity:
| PAF805Mu01-200ul | 200ul | £223.00 |
Quantity:
| PAF805Mu01-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ABIN-2; ABIN2; FLIP1; KLIP; A20-binding inhibitor of NF-kappa-B activation 2; Fetal liver LKB1-interacting protein
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Tumor Necrosis Factor Alpha Induced Protein 3 Interacting Protein 2
Reactivity:
Hu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Tumor Necrosis Factor Alpha Induced Protein 3 Interacting Protein 2 (TNIP2) | RPF805Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||